Home > Insider Trading > Filing (0000890465-14-000008)

Filing Details

Accession Number:: 0000890465-14-000008
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-01-09 16:53:47
Reporting Period:: 2014-01-07

Filing Date:: 2014-01-09
Accepted Time:: 2014-01-09 16:53:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
890465	Nps Pharmaceuticals Inc	NPSP	Biological Products, (No Disgnostic Substances) (2836)	870439579

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1192128	M Luke Beshar	550 Hills Drive Bedminster NJ 07921	Evp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-01-08	31,588	$3.34	90,768	No	4	M	Direct
Common Stock	Disposition	2014-01-08	31,588	$35.01	59,180	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Acquisiton	2014-01-07	8,625	$0.00	8,625	$3.34
Common Stock	Stock Options	Disposition	2014-01-08	31,588	$0.00	31,588	$3.34

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
106,376		2020-02-19	No	4	A	Direct
74,788		2020-02-19	No	4	M	Direct

Footnotes

The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 12, 2013.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $35.00 and $35.02. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On January 7, 2014, the performance criteria for 8,625 of these options was satisfied when the FDA accepted the BLA for Natpara for the treatment of hypoparathyroidism. As of January 7, 2014, the performance criteria and the time-based criteria for 71,156 of these options has been satisfied. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of January 8, 2014, the performance criteria and the time-based criteria for 71,156 of these options has been satisfied. The options become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.